Los medicamentos ante las nuevas realidades económicas
(1997; 272 páginas) [English]
Table of Contents
View the documentNOTA SOBRE LOS AUTORES
View the documentPRESENTACIÓN
View the documentPRÓLOGO
View the documentGLOSARIO
Open this folder and view contentsI. EL ENTORNO ECONOMICO GLOBAL
Close this folderII. LA REFORMA DE LOS SISTEMAS DE SALUD
Close this folderII.1. El impacto sobre los medicamentos de la contención del gasto y las reformas en la asistencia sanitaria, por Elias Mossialos
View the document1. INTRODUCCIÓN
Open this folder and view contents2. LAS MEDIDAS DE CONTENCIÓN DE GASTOS
Open this folder and view contents3. LAS SOLUCIONES A LARGO PLAZO
View the document4. CONCLUSIONES
View the documentBIBLIOGRAFÍA
Open this folder and view contentsII.2. La reforma de la atención a la salud en América Latina. El rol del Estado y los medicamentos esenciales, por Alberto Infante
Open this folder and view contentsII.3. Regulación, políticas y medicamentos esenciales, por Juan Ignacio Arango F.
Open this folder and view contentsIII. LAS TRANSFORMACIONES DE LA INDUSTRIA FARMACÉUTICA
Open this folder and view contentsIV. SINTESIS Y PREVISIONES
View the documentBIBLIOTECA CIVITAS ECONOMÍA Y EMPRESA - COLECCIÓN ECONOMÍA - SERIE TRATADOS Y MANUALES
View the documentCUBIERTA POSTERIOR
 

BIBLIOGRAFÍA

ABEL-SMITH, B. y MOSSIALOS, E. (1994): Cost Containment and Health Care Reform: A Study of the European Union, The European Commission, Luxemburgo. También en Health Policy, vol. 28, pp. 89-132.

ABEL-SMITH, B.; FIGUERAS, J.; HOLLAND, W.; McKEE, M. y MOSSIALOS, E. (1995a): Choices in Health Policy: An Agenda for the European Union, Aldershot, Dartmouth.

ABEL-SMITH, B. (1995): Health Care in the OECD Countries, ponencia presentada al congreso anual de la Asociación Española de Economía de la Salud, Valencia.

BUREAU EUROPÉEN DES UNIONS DES CONSOMMATEURS (BEUC) (1989): Drug Prices and Drug Legislation in Europe, Bruselas.

CHAPPEL, N. L. (1993): «The Future of Health Care in Canada», Journal of Social Policy, vol. 22, núm. 4, p. 495.

COSTAIN, D. y WOLFSON, G. (1994): Don't Blame the Elderly, The Health Summary.

CUDEX, C. (1986): QUALYS and their Use by the Health Service, Discussion Paper núm. 20, Centre for Health Economics, York University.

CUENI, T. (1994): «An Industrial Policy for the Pharmaceutical Industry in Europe», Paper presented at a workshop organized by the London School of Economics and Pharmaceutical Partners for Better Healthcare, on Health Care Reforms and the Role of the Pharmaceutical Industry, septiembre.

DRUMMOND, M. F. et al. (1987): Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, Oxford.

FATTORE, G. (1994): «Pharmaceutical Policies in Italy», Paper presented at a workshop organized by the London School of Economics and Pharmaceutical Partners for Better Healthcare, in Health Care Reforms and the Role of the Pharmaceutical Industry, septiembre.

FINEBERG, H. V. y HIATT, H. H. (1979): «Evaluation of Medical Practices: The Case for Technology Assessment», The New England Journal of Medicine, vol. 301, núm. 20, pp. 1086-1091.

FUCHS, V. R. y GARBER, A. M. (1990): «The New Technology Assessment», The New England Journal of Medicine, vol. 323, núm. 10, pp. 673-677.

GELIJNS, A. C. (ed.) (1992): Technology and Health Care in an Era of Limits, National Academy Press, Washington.

GLASSER, J. H. (1988): «The Aims and Methods of Technology Assessment», Health Policy, vol. 9, pp. 241-250.

GRIMSHAW, J, y RUSSEL, I. T. (1993): «Effect of Clinical Guidelines on Medical Practices: A Systematic Review of Rigorous Evaluations», The Lancet, núm. 342, pp. 1317-1322.

IOO (1995): Beoordeling ABDA-Prijsvergelijking Geneesmiddelen, IOO, Den Haag.

LE PEN, C. (1994): Health Care Reforms in France, Estudio presentado en un seminario organizado por LSE Health, Londres.

LOMAS, J. et al. (1988): «A Taxonomy and Critical Review of Tested Strategies for the Application of Clinical Practice Recommendations: From “Official” to Individual Clinical Policy», American Journal of Preventive Medicine, vol. 4 (suplemento), pp. 77-84.

MINISTRY OF HEALTH WELFARE AND CULTURAL AFFAIRS (1992): Choices in Health Care, The Netherlands.

MOSSIALOS, E. (1995): Methodological Problems in Pharmaceutical Price Comparisons, Office for Official Publications of the European Communities, Luxemburgo.

MOSSIALOS, E. y ABEL-SMITH, B. (1995): Cost Containment and Health Care Reforms in Six European Countries (Germany, Spain, UK, Ireland, Belgium and France), 1st. Report, The European Commission, Bruselas.

MOSSIALOS, E.; RANOS, C. y ABEL-SMITH, B. (eds.) (1994): Cost Containment Pricing and Financing of Pharmaceuticals in the European Community: The Policy Makers' View, LSE Health and Pharmetrica S.A., Londres y Atenas.

MOSSIALOS, E.; KANAVOS, P. y ABEL-SMITH, B. (1994a): Policy Options for Pharmaceutical Research and Development in the European Union, Parlamento Europeo, Bruselas.

NHS MANAGEMENT EXECUTIVE (1993): First Report to the Central Research and Development Committee from the Standing Group on Health Technology, NHS Management Executive, Leeds.

OFFICE OF HEALTH ECONOMICS (1995): Compendium of Health Statistics, Londres.

ROBINSON, R. y LE GRAND, J. (eds.) (1994): Evaluating the NHS Reforms, The King's Fund Institute, Londres.

ROSSER, R. M. y WATTS, V. C. (1972): «The Measurement of Hospital Output», International Journal of Epidemiology, vol. 1, núm. 4, pp. 361-369.

ROSSER, R. y KIND, P. (1978): «A Scale of Valuation of States of Illness: Is There a Consensous», International Journal of Epidemiology, vol. 7, núm. 4, pp. 347-358.

ROVIRA, J. (1994): «The Impact of the Single European Market on Pharmaceutical Policies», Paper presented at a workshop organized by the London School of Economics and Pharmaceutical Partners for Better Healthcare, on Health Care Reforms and the Role of the Pharmaceutical Industry, septiembre.

SANDIER, S. (1987): Le Vieillissement de la Population en Europe et le Cout des Soins Médicaux, Credes, Paris.

SCHULENBURG, V. D.; GRAF, J. M. y SCHOFFSKI, O. (1993): Implications of the Structural Reform of Healthcare Act on the Referral and Hospital Admission Practice of Primary Care Physicians, University of Hanover, Discussion Paper núm. 34.

SCHWABE, U. y PAFFRATH, D. (eds.) (1994): Arzneiverordnungs-Report 1994, Gustav Fisher Verlag, Stuttgart.

STOCKING, B. (ed.) (1988): Expensive Health Technology: Regulatory and Administrative Mechanisms in Europe, Oxford University Press, Oxford.

WENNBERG, J. E. et al. (1987) «Are Hospital Services Rationed in New Haven or Over-utilised in Boston?», The Lancet, I, pp. 1185-1189.

WENNBERG, J. E. (1992): Innovation and the Politics of Limits in a Changing Health Care Economy, en GELIJNS 1992, pp. 16-17.

US GENERAL ACCOUNTING OFFICE (1994): Medical Malpractice: Maine's Use of Practice Guidelines to Reduce Costs, US Government Printing Office, GAO/HRD-94-8, Washington.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019